Certara (NASDAQ:CERT) Updates FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.420-0.460 for the period, compared to the consensus estimate of 0.500. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $422.4 million.

Certara Stock Performance

NASDAQ:CERT traded up $0.08 during mid-day trading on Thursday, hitting $12.41. The company’s stock had a trading volume of 191,824 shares, compared to its average volume of 1,244,847. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business’s fifty day moving average is $12.39 and its two-hundred day moving average is $11.63. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -61.35, a PEG ratio of 9.29 and a beta of 1.57. Certara has a 1 year low of $9.41 and a 1 year high of $19.87.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Stephens reissued an “overweight” rating and set a $17.00 price target on shares of Certara in a report on Thursday. Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. TD Cowen started coverage on shares of Certara in a research note on Thursday. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Certara presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.64.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.